Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for targeting cancer cells by disrupting transcriptional processes essential for tumor growth and survival. It is investigated for its antitumor activity in hematological malignancies and solid tumors. Due to its mechanism of inducing apoptosis in cancer cells with minimal effect on normal cells, it serves as a valuable tool compound in preclinical studies for developing targeted cancer therapies. Its sulfonate salt form enhances solubility, supporting in vitro and in vivo experimentation.